Drug Profile
Vactosertib - MedPacto
Alternative Names: EW-7197; NOV 1301; TEW-7197Latest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Ewha Womans University
- Developer AstraZeneca; Case Comprehensive Cancer Center; MedPacto; Merck & Co; National OncoVenture; Samsung Medical Center; Yonsei University Health System
- Class Aniline compounds; Antineoplastics; Fluorine compounds; Imidazoles; Pyridines; Small molecules; Triazoles
- Mechanism of Action Transforming growth factor beta type I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bladder cancer; Fibroma; Gastric cancer; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer
- Phase I/II Colorectal cancer; Myelodysplastic syndromes; Osteosarcoma
- No development reported Solid tumours
Most Recent Events
- 09 Dec 2023 Efficacy, pharmacodynamics and adverse events data from a phase I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 08 Dec 2023 MedPacto anticipates IND approval from US FDA for phase IIb/III trial for Colorectal cancer in 2023
- 08 Dec 2023 MedPacto plans a phase IIb/III trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA and South Korea (PO) in 2024